Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma By Ogkologos - March 3, 2025 680 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Talking About Your Sexual Orientation and Gender Identity With Your Cancer... August 10, 2021 EMA Recommends Extension of Indications for Trastuzumab Deruxtecan to Include Treatment... March 21, 2025 Progression-Free Survival and Overall Survival Significantly Longer with Lenvatinib Plus Pembrolizumab... January 26, 2022 When He Said His Mother-In-Law Was Going To Live In The... March 6, 2019 Load more HOT NEWS Rate of Suicides Related to Cancer Is Declining Government update on the Clinical Research Vision: More needed to go... Plant-Based Diets and a New Treatment Combination for Prostate Cancer: Research... FDA Approves Relugolix for Advanced Prostate Cancer
